In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.
【저자키워드】 Vaccines, 【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Efficacy, COVID-19 vaccine, pandemic, Trial, knowledge, COVID-19 pandemic, severe acute respiratory syndrome Coronavirus, COVID-2019, Severe acute respiratory syndrome, vaccine candidate, respiratory, Phase 3, Coronavirus-2, immune correlates, acute respiratory syndrome, Endpoint, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus-2, help, candidate, approval, vaccine candidates, facilitate, immune correlate, 【제목키워드】 Evidence, Endpoint,